Researchers from the Center of Excellence for the Acceleration of Harm Reduction (CoEHAR) involved in the Replica project have discovered that switching to electronic cigarettes and heated tobacco products can reduce the incidence of vascular damage and smoking-related diseases. The findings challenge the prevailing misconception that using e-cigarettes and heated tobacco products is just as harmful as smoking.
The study has been published by an independent laboratory affiliated with the Replica Project, whose scientists are world leaders in harm reduction. The latest research assessed the damage caused to endothelial cells, which release substances that control the dilation and contraction of blood vessels, by cigarette smoke compared to electronic cigarettes and heated tobacco products.
Damage to the inner lining of blood vessels known as endothelial damage is a primary pathology that leads to diseases such as atherosclerosis, with smoking being the main culprit. Smoking can impair the normal function of the endothelium, cause damage to the vascular system, and lead to the development of high blood pressure and atherosclerosis. Smoking and exposure to smoke toxins are related to the impairment of the repair mechanism needed for endothelial homeostasis, such as the inhibition of endothelial cell migration.
Reducing exposure to smoke toxins may mitigate the harmful effects on endothelial and cardiovascular disease development. Numerous international studies have investigated the impact of smoking on endothelial cell migration and associated vascular damage, particularly a study by Taylor et al. (2017). Compared to cigarette smoke, exposure to electronic cigarette aerosol significantly reduces inhibition of in vitro (in a test tube) endothelial cell migration. This means that endothelial cells exposed to electronic cigarette aerosol retain their ability to effectively heal small wounds in blood vessels, unlike those exposed to cigarette smoke and toxins, which severely limit their wound repair capacity.
One of CoEHAR's most successful projects is the Replica project, in which researchers have replicated some of the most significant international studies in the field of reducing tobacco harm via an independent laboratory network. They have demonstrated a reduction in the toxicity of electronic cigarettes and have established reference standards for scientific research. The goal of CoEHAR's scientists is to conduct a multicenter replication study to validate the results of Taylor and his colleagues.
A study titled "Comparative evaluation of e-cigarette aerosol and cigarette smoke on endothelial cell migration: a replication study" compared the effects of three commercial e-cigarette delivery systems and traditional cigarettes. Following international scientific standards and utilizing the latest technology and tools, the data collected by researchers at CoEHAR confirmed the findings of Taylor and colleagues: e-cigarettes do not induce inhibition of endothelial cell migration in vitro compared to cigarette smoke, thus reducing harm caused by tobacco smoke. Furthermore, CoEHAR researchers compared the results of two different heated tobacco products, which demonstrated significantly less impact than observed with cigarette smoke.
According to Professor Massimo Caruso, co-project leader of the Replica initiative, "As previously demonstrated by the Replica research team, the harm caused by electronic nicotine delivery systems is significantly lower than the harm caused by cigarette smoke. An interesting fact is that using non-combustible products can reduce vascular damage and prevent the likelihood of smoking-related diseases such as atherosclerosis and hypertension. Our research once again challenges the notion that electronic cigarettes or heated tobacco will cause similar damage to combustible cigarettes.
Statement:
This article is compiled from third-party information and is only meant for industry-related communication and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of its content. The translation of this article is only intended for industry exchange and research.
Due to limitations in the translation process, the translated article may not fully reflect the original expression. Therefore, please refer to the original article for accuracy.
2FIRSTS is fully aligned with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The compilation of information is subject to the copyright ownership of the original media outlet and author. If there is any infringement, please contact us to request removal.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
